阿司匹林联合曲妥珠单抗对HER-2阳性乳腺癌细胞增殖和凋亡的影响#br# #br#

目的 探讨阿司匹林联合曲妥珠单抗对表皮生长因子受体2（HER 2）阳性乳腺癌SKBR 3细胞增殖和凋亡的影响。方法 将SKBR 3细胞分为对照组、阿司匹林组（5 mmol／L）、曲妥珠单抗组（30 μg／ml）和联合组（5 mmol／L 阿司匹林+30 μg／ml 曲妥珠单抗），采用MTT法、流式细胞术分别观察不同药物处理对SKBR-3细胞增殖和凋亡的影响。结果 阿司匹林组SKBR 3细胞增殖率为（79.6±2.61）％，曲妥珠单抗组为（48.2±3.35）％，联合组为（21.5±1.66）％，组间差异有统计学意义（P＜0.05）。阿司匹林、曲妥珠单抗联合作用指数（CI）为1.0，属于叠加作用。阿司匹林组SKBR 3细胞凋亡率为（273±347）％，曲妥珠单抗组为（35.3±2.80）％，联合组为（56.2±3.95）％，组间差异有统计学意义（P＜0.05）。结论 阿司匹林联合曲妥珠单抗能有效抑制HER-2阳性乳腺癌细胞的增殖，两药联合有可能成为HER 2阳性乳腺癌的临床治疗新模式。

Effects of aspirin combined with trastuzumab on proliferation and apoptosis of HER-2 positive breast cancer cells#br# #br#

ObjectiveTo investigate the effects of aspirin combined with trastuzumab on proliferation and apoptosis of HER-2 positive breast cancer cell line SKBR-3.MethodsThe SKBR-3 cells were divided into four groups： control group， aspirin group （5 mmol／L）， trastuzumab group （30 μg／ml） and combination group （5 mmol／L aspirin+30 μg／ml trastuzumab）. MTT assay and flow cytometry were used to observe the effects of different drug treatment on cell proliferation and apoptosis. ResultsMTT assays showed that the relative proliferation rate of SKBR 3 cells was （79.6±2.61）％ in aspirin group， （48.2±3.35）％ in trastuzumab group and （21.5±166）％ in combination group. Compared with aspirin group or trastuzumab group， the cell proliferation of combination group was significantly inhibited （P＜0.05）. Two drugs combined effect index was 10 of a superimposition effect. The apoptosis assays showed that the relative apoptotic rate of cells was （27.3±3.47）％ in aspirin group， （35.3±2.80）％ in trastuzumab group and （56.2±3.95）％ in combination group. Compared with aspirin group or trastuzumab group， the cell apoptosis of combination group was significantly increased （P＜0.05）. ConclusionAspirin combined with trastuzumab can effectively inhibit the growth of HER-2 positive breast cancer cells， which may be a new model for the clinical treatment of HER-2 positive breast cancer.